<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558207</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 197-205</org_study_id>
    <nct_id>NCT00558207</nct_id>
  </id_info>
  <brief_title>A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label randomized phase 2 study designed to assess the&#xD;
      progression free survival (PFS) of patients with untreatment and unresectable pancreatic&#xD;
      cancer following treatment with either ARQ 197 or gemcitabine. The study will also evaluate&#xD;
      other efficacy and safety endpoints including overall response rate, overall survival and&#xD;
      adverse events in the two treatment arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label randomized phase 2 study designed to evaluate the PFS of&#xD;
      treatment-naïve patients with unresectable (locally advanced or metastatic) pancreatic&#xD;
      adenocarcinoma following treatment with either ARQ 197 (ARQ arm) or gemcitabine alone (GEM&#xD;
      arm). The study will also evaluate other efficacy and safety parameters including ORR, OS and&#xD;
      adverse events in the two treatment arms. Patients randomly assigned to the GEM arm will&#xD;
      receive gemcitabine alone. Patients assigned to the ARQ arm will receive oral ARQ 197 alone.&#xD;
&#xD;
      ARQ 197 is an investigational oral drug supplied as capsules in multiple strengths. For the&#xD;
      study initial shipment the capsules were 120 mg each, 30 count. In the ARQ arm, patients will&#xD;
      take 120 mg of ARQ 197 twice daily, once in the morning and once in the evening one hour&#xD;
      prior to or two hours after a meal. ARQ 197 treatment will be continued until unacceptable&#xD;
      toxicity, documented progression of disease, or another discontinuation criterion is met.&#xD;
&#xD;
      Gemcitabine is a commercially available drug for the treatment of patients with locally&#xD;
      advanced or metastatic adenocarcinoma of the pancreas. In the GEM arm, gemcitabine will be&#xD;
      administered by intravenous infusion over 30 minutes at a dose of 1000 mg/m2. The dosing&#xD;
      schedule of gemcitabine will be once weekly for the first cycle (4 weeks), then once weekly&#xD;
      for 3 consecutive weeks followed by a week of rest for each subsequent cycle. Gemcitabine&#xD;
      therapy will be continued until unacceptable toxicity, documented progression of disease, or&#xD;
      another discontinuation criterion is met.&#xD;
&#xD;
      A treatment cycle is defined as 28 days for both treatment arms. Cycles may be repeated every&#xD;
      4 weeks (28 days) based on toxicity and response. The assigned treatment should continue&#xD;
      until unacceptable toxicity, disease progression (clinical or radiological) or another&#xD;
      discontinuation criterion is met.&#xD;
&#xD;
      Tumor evaluations: Tumor evaluations will be performed in 8-week intervals. Tumor response&#xD;
      (complete response, partial response, stable disease, progressive disease and ORR) will be&#xD;
      evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).&#xD;
&#xD;
      Progression-free survival: The time of disease progression-free will be calculated from&#xD;
      randomization until disease progression per RECIST or death due to any cause. Patients who&#xD;
      are alive and progression free will be censored at the date of their last tumor evaluation.&#xD;
&#xD;
      Overall survival: Overall survival time will be calculated from the date of randomization&#xD;
      until death due to any cause.&#xD;
&#xD;
      Safety assessments: Data on vital signs, physical examination, adverse events, serum&#xD;
      chemistry, hematological laboratory tests, and electrocardiograms will be collected.&#xD;
&#xD;
      This study is designed to establish potential efficacy of ARQ 197 in treatment naive&#xD;
      pancreatic cancer patients in a controlled, randomized study. The sample size of 30 Evaluable&#xD;
      patients per treatment group is considered adequate to provide meaningful estimates of the&#xD;
      PFS and ORR and OS rates, however, this study is not powered to show statistically&#xD;
      significant differences between the treatment groups. Therefore, the analyses will be&#xD;
      primarily descriptive in nature. Taking into account an anticipated&#xD;
      drop-out/loss-to-follow-up rate of 20%, the total sample size will be 72 patients.&#xD;
&#xD;
      Primary and secondary objectives will be analyzed in the two treatment arms using appropriate&#xD;
      patient populations and statistical methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate progression-free survival (PFS) in patients receiving ARQ 197 versus gemcitabine.</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate overall response rate (ORR) in patients receiving ARQ 197 versus gemcitabine</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate 6-month and 1-year overall survival (OS) rates in patients treated with ARQ197 versus gemcitabine</measure>
    <time_frame>6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further characterize the safety profile of ARQ 197</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARQ 197</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 197</intervention_name>
    <description>120 mg capsule administered twice daily for 240 mg total daily dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide signed and dated informed consent prior to study-specific screening&#xD;
             procedures&#xD;
&#xD;
          2. ≥ 18 years old&#xD;
&#xD;
          3. Histologically or cytologically confirmed locally advanced or metastatic unresectable&#xD;
             pancreatic adenocarcinoma&#xD;
&#xD;
          4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
&#xD;
          5. Karnofsky performance status (KPS) ≥ 70%&#xD;
&#xD;
          6. Male or female patients of child-producing potential must agree to use double barrier&#xD;
             contraception, oral contraceptives or avoidance of pregnancy measures during the study&#xD;
             and for 90 days after the last day of treatment&#xD;
&#xD;
          7. Females of childbearing potential must have a negative serum pregnancy test&#xD;
&#xD;
          8. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of&#xD;
             normal (ULN) or ≤ 5 × ULN with metastatic liver disease&#xD;
&#xD;
          9. Hemoglobin ≥ 10 g/dl&#xD;
&#xD;
         10. Total bilirubin ≤ 1.5 × ULN&#xD;
&#xD;
         11. Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
         12. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L&#xD;
&#xD;
         13. Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received any prior therapy for the treatment of their pancreatic malignancy (including&#xD;
             chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or&#xD;
             irradiation, whether conventional or investigational)&#xD;
&#xD;
          2. Central nervous system metastases&#xD;
&#xD;
          3. Pregnant or breastfeeding&#xD;
&#xD;
          4. Significant gastrointestinal disorder, in the opinion of the Principal Investigator&#xD;
             (e.g. Crohn's disease, ulcerative colitis, extensive gastric resection)&#xD;
&#xD;
          5. Unable or unwilling to swallow ARQ 197 capsules twice daily&#xD;
&#xD;
          6. Other cancer within the last five years, with the exception of adequately treated&#xD;
             cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          7. Significant co-morbid conditions that in the opinion of the Investigator would impair&#xD;
             study participation&#xD;
&#xD;
          8. Known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cezary Szczylik, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Onkologii WIM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janusz Pawlega, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oddzial Kliniczny Kliniki Onkologii</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Koralewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oddzial Chemioterapii Krakow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilia Filipczyk-Cisarz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oddzial Chemioterapii Dolnoslaskie Centrum Onkologii</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ewa Kilar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regionalny Szpital Specjalistyczny Latawiec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Sawrycki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oddzial Onkologii Klinicznej im L Rydygiera</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oddzial Kliniczny Kliniki Onkologii Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Chemioterapii, Wojewodzki Szpital Specjalistyczny</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział Onkologii Klinicznej, Regionalny Szpital Specjalistyczny &quot;Latawiec&quot;</name>
      <address>
        <city>Swidnica</city>
        <zip>58-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział Onkologii Klinicznej SP ZOZ Wojewódzki Szpital Zespolony im. L. Rydygiera</name>
      <address>
        <city>Torun</city>
        <zip>53/59</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Onkologii WIM Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział Chemioterapii Dolnośląskie Centrum Onkologii</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Latvia</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <disposition_first_submitted>February 21, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 21, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 25, 2013</disposition_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>pancreas cancer</keyword>
  <keyword>Locally advanced or metastatic pancreatic adenocarcioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

